Protein Kinases as Drug Targets
This timely guide to kinase inhibitor drug discovery is the first to cover the entire drug pipeline, from target identification to compound development and clinical application. Edited by pioneers in the field, on the drug development side this ready reference discusses classical medicinal chemistry approaches as well as current chemical genomics strategies. On the clinical side, both current and future therapeutic application areas for kinase inhibitor drugs are addressed, with a strong focus on oncology drugs. Backed by recent clinical experience with first-generation drugs in the battle against various forms of cancer, this is crucial rea…
Mehr
CHF 156.00
Preise inkl. MwSt. und Versandkosten (Portofrei ab CHF 40.00)
Versandkostenfrei
Produktdetails
Weitere Autoren: Folkers, Gerd (Reihe Hrsg.) / Kubinyi, Hugo (Reihe Hrsg.) / Klebl, Bert (Hrsg.) / Müller, Gerhard (Hrsg.) / Hamacher, Michael (Hrsg.)
- ISBN: 978-3-527-63349-4
- EAN: 9783527633494
- Produktnummer: 13862505
- Verlag: Wiley-Vch
- Sprache: Englisch
- Erscheinungsjahr: 2011
- Seitenangabe: 396 S.
- Plattform: EPUB
- Masse: 4'759 KB
- Auflage: 2. Aufl.
Über den Autor
Bert Klebl is an expert in small molecule based drug discovery. Currently, he is managing director and CSO of Lead Discovery Center GmbH, which was started by Max-Planck Innovation and the Max-Planck Society. Before, he was at GPC Biotech, Axxima Pharmaceuticals and Aventis (Hoechst Marion Roussel). A biochemist by training, he graduated from the University of Konstanz, Germany, and did post-doctoral work at the Biotechnology Research Institute in Montréal, Canada. Gerhard Müller received his PhD in Organic Chemistry in 1992 from the Technical University of Munich, working with Horst Kessler. After two years in the Medicinal Chemistry Department of Glaxo Verona (Italy), he joined the Central Research Facility of Bayer AG in Leverkusen. From 2001 to 2003 he headed the chemistry department of Organon's Lead Discovery Unit is Oss, Netherlands. In 2003 he was nominated CSO of Axxima Pharmaceuticals AG in Munich, and upon its acquisition through GPC Biotech AG in 2005, he became GPC's Vice President Drug Discovery. Since 2008 he is CSO and Managing Director of Proteros Fragments GmbH, specializing in fragment-based lead generation. Apart from numerous scientific articles and patents, he co-edited the Chemogenomics in Drug Discovery book of this series on medicinal chemistry. Michael Hamacher studied biology at the Heinrich-Heine-Universität in Düsseldorf, Germany. Subsequent to his PhD, he joined the Medizinisches Proteom-Center, Ruhr-Universität Bochum, Germany, and became Head of Administration of the MPC, responsible for the implementation and the strategical planning of the Human Brain Proteome Project under the roof of the Human Proteome Organisation (HUPO BPP) among others. In 2008, he moved to the Lead Discovery Center GmbH, Dortmund, Germany, for the same position, focussing on preparing national as well as international funding applications, on project management, budgeting as well as human resources. He applied and implemented numerous projects in early pharmaceutical research.
100 weitere Werke von Raimund (Reihe Hrsg.) Mannhold:
Bewertungen
Anmelden